



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ladiratumab vedotin

Cat. No.:	HY-P99683
CAS No.:	1629760-29-7
Target:	Antibody-Drug Conjugates (ADCs)
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	<p>Ladiratumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC₅₀: 5.6 nM for LIV-1). Ladiratumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratumab vedotin can be used for research of breast cancer^{[1][2][3][4]}.</p>								
In Vitro	<p>Ladiratumab vedotin (LIV-1+ cells) activates the ER stress response via the activation of ATF6 and phosphorylation of IRE1 and eIF2a^[3].</p> <p>Ladiratumab vedotin (LIV-1+ cells) releases ATP and HMGB1 into the supernatant (hallmarks of ICD^[3]).</p> <p>Ladiratumab vedotin (0-100 ng/mL) shows cytotoxic activity against MCF-7 cell line^[4].</p> <p>Ladiratumab vedotin (1 µg/mL, 24 h) internalizes, traffics to the lysosome, and disrupts the microtubule network in MCF-7 cells^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[4]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>MCF-7</td> </tr> <tr> <td>Concentration:</td> <td>0-100 ng/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>96 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell viability with an EC₅₀ value of 6.3 ng/mL.</td> </tr> </table>	Cell Line:	MCF-7	Concentration:	0-100 ng/mL	Incubation Time:	96 h	Result:	Inhibited cell viability with an EC ₅₀ value of 6.3 ng/mL.
Cell Line:	MCF-7								
Concentration:	0-100 ng/mL								
Incubation Time:	96 h								
Result:	Inhibited cell viability with an EC ₅₀ value of 6.3 ng/mL.								
In Vivo	<p>Ladiratumab vedotin (3 mg/kg, i.p., every 4 days) results tumor regression in MCF-7 breast cancer cell xenograft model^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>MCF-7 breast cancer cell xenograft model^[4]</td> </tr> <tr> <td>Dosage:</td> <td>3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p., every 4 days</td> </tr> <tr> <td>Result:</td> <td>Delayed tumor growth.</td> </tr> </table>	Animal Model:	MCF-7 breast cancer cell xenograft model ^[4]	Dosage:	3 mg/kg	Administration:	i.p., every 4 days	Result:	Delayed tumor growth.
Animal Model:	MCF-7 breast cancer cell xenograft model ^[4]								
Dosage:	3 mg/kg								
Administration:	i.p., every 4 days								
Result:	Delayed tumor growth.								

Animal Model:	BALB/C mice (PK assay) ^[4]
Dosage:	3 mg/kg
Administration:	i.v., single
Result:	Showed a terminal half-life of 6.8 days.

REFERENCES

- [1]. Rizzo A, et al. Ladiratumumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. *Expert Opin Investig Drugs*. 2022 Jun;31(6):495-498.
- [2]. Jane Lowe Meisel, et al. Phase 1b/2 study of ladiratumumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress). *Journal of Clinical Oncology*. 2022 40:16_suppl, TPS1127-TPS1127.
- [3]. Anthony T. Cao, et al. Abstract 2742: Additional mechanisms of action of ladiratumumab vedotin contribute to increased immune cell activation within the tumor. *Cancer Res (2018) 78 (13_Supplement): 2742*.
- [4]. Sussman D, et al. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. *Mol Cancer Ther*. 2014 Dec;13(12):2991-3000.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA